reSee.it - Related Video Feed

In this episode of Cold Fusion, Dagogo Altraide discusses how CRISPR technology is restoring sight to individuals with genetic diseases like Leber congenital amaurosis (LCA). CRISPR, a gene-editing tool, allows for precise DNA modifications, enabling researchers to correct genetic defects. Two studies in 2021 showed significant vision improvements in participants after CRISPR treatment, with some regaining color vision. While the results are promising, the treatment is still experimental and not universally effective. Researchers are optimistic about future applications of CRISPR for various diseases, but caution is advised regarding potential unforeseen consequences and ethical concerns surrounding genetic modification.

David Sinclair lays out a personal narrative of why aging is a solvable problem, beginning with a pivotal memory of his Hungarian grandmother and a childhood realization that aging and death aren’t inevitable. He explains his long-term view that aging is a central, modifiable biological process, not a natural fate, and he describes a research program aiming to reset the body's age by reinstating a youthful epigenetic state. The conversation then moves into practical demonstrations from his lab, including work on reversing age in cells, extending lifespan in animals, and the first human trial aimed at restoring function in the eye. Sinclair emphasizes safety and cautious steps in translating animal and primate work to humans, noting that age reversal could first appear as treatments for age-related diseases rather than a blanket rejuvenation, with the eye model serving as a safer starting point. The discussion expands to how aging is driven by epigenetic information and how the body maintains identity through gene expression; aging is framed as an identity crisis in aging cells caused by erasure of epigenetic marks and mislocalization of the proteins that control which genes are active. He argues that turning back this epigenetic clock could simultaneously address multiple diseases, including cancer, neurological disorders, and degenerative conditions, because aging underpins these illnesses. The podcast also tackles lifestyle choices, such as diet, fasting, exercise, sleep, and stress management, highlighting that behavior strongly modulates aging through cellular stress responses and metabolic pathways. They discuss the feasibility and timeline for broad access to such medicines, the regulatory and geopolitical landscape, and the societal implications of longer, healthier lives. The tone remains exploratory and forward-looking, with Sinclair acknowledging remaining uncertainties, the need for rigorous trials, and the ethical and economic questions that will accompany a future in which aging can be slowed, paused, or reversed.

David Sinclair discusses the potential for reversing aging, emphasizing that aging is a loss of information rather than mere physical damage. He believes there is no upper limit to human lifespan, citing examples from other species that live significantly longer. Sinclair's research focuses on epigenetics, revealing that every cell contains a backup copy of information that can be accessed to rejuvenate tissues. He highlights recent breakthroughs in resetting biological age in mice and the promise of similar therapies for humans, particularly in reversing conditions like blindness. Sinclair predicts that within the next two years, human clinical trials for age reversal will begin. He stresses the importance of lifestyle choices in maintaining a youthful biological age and mentions ongoing research to develop affordable age-reversal therapies. Sinclair's work aims to make these advancements accessible to all, not just the wealthy, and he is optimistic about the future of longevity science.

In this episode of the Huberman Lab, Dr. Tony Wyss-Coray discusses research on aging, focusing on how factors in young blood and in blood after exercise can influence aging in the brain and other tissues. The conversation highlights experiments where old animals exposed to young blood showed reactivated brain stem cells, reduced inflammation, and improved memory, suggesting that certain circulating proteins decline with age while others promote regeneration. Wyss-Coray explains how the aging process is not uniform across organs: different tissues age at different rates, and scientists can measure organ-specific aging through proteomic analyses of blood and cerebrospinal fluid. The discussion covers how young-blood factors might act directly on cells, but also how aging involves inflammatory molecules that opposingly impair function. The guests describe efforts to translate these findings to humans, including therapeutic plasma exchange and fractionated blood products, as well as small clinical trials in neurodegenerative diseases. They emphasize that aging research is moving toward identifying multiple factors that act in concert rather than a single magic bullet, with attention to how organ-specific aging can be predicted and potentially reversed. The conversation also addresses the balance between vitality-enhancing interventions (such as exercise, sunlight, and certain hormonal or growth-factor pathways) and longevity, acknowledging the tradeoffs scientists often observe, such as growth hormone–IGF-1–related vitality versus lifespan effects. Throughout, the speakers stress the importance of rigorous, controlled studies and caution against unproven therapies, including out-of-country stem-cell procedures. They also explore how lifestyle factors—sleep, light exposure, social interaction, diet, and physical activity—intersect with circulating factors to shape healthspan. The episode closes with reflections on future directions, including organ- and cell-type aging maps, the potential for personalized interventions guided by proteomic and wearable data, and the prospect of bringing science-backed tools to the public in a careful, clinically validated way.

Dax Shepard hosts David Sinclair, an Australian biologist and professor of genetics known for his research on aging and longevity. Sinclair discusses his background, including his PhD from the University of New South Wales and his work at Harvard Medical School since 1999. He emphasizes the importance of longevity research, distinguishing it from anti-aging, which he associates with snake oil salesmen. Sinclair believes that understanding aging can lead to significant advancements in medicine, arguing that aging should not be accepted as a natural process but rather as a condition that can be treated. Sinclair explains that traditional medicine focuses on diseases rather than the aging process itself, which he sees as a missed opportunity. He discusses the role of the epigenome in aging, suggesting that it deteriorates over time, leading to inefficient gene expression. Sinclair's lab has made breakthroughs in reversing aging in mice, using a combination of embryonic genes to reset cellular age. He mentions the potential for this technology to be applied to humans, with hopes of clinical trials in the near future. The conversation touches on the societal implications of extended lifespans, including ethical dilemmas and the potential for increased suicide rates if people feel trapped in a long life. Sinclair acknowledges the need for discussions about the consequences of longevity research, including economic impacts and the potential for societal changes in perceptions of age and wisdom. Sinclair expresses optimism about the future of aging research, predicting breakthroughs within the next five years that could lead to significant advancements in health and longevity. He emphasizes the importance of public discourse on these topics, advocating for transparency and direct communication between scientists and the public.

Researchers, led by Dr. Sinclair at Harvard, are exploring health regeneration and the aging process. They discovered that aging is linked to the epigenome, which controls DNA expression. Experiments on mice showed that altering epigenetic information can reverse aging effects, with treated mice running significantly longer. The focus is on boosting NAD levels, which decline with age, using compounds like NMN. Additionally, the Yamanaka factors may enable regeneration of damaged cells. While still in research, these findings could improve health and quality of life in aging populations.

In this episode of "Moonshots," Peter Diamandis interviews Dr. David Sinclair, a leading scientist in longevity and age reversal. They discuss the potential for age reversal technologies that could allow individuals to take a pill for a few weeks and effectively become younger. Sinclair explains that aging is primarily an issue of the epigenome, which can be reset without cloning. He shares insights from his research, including the ability to reverse aging in cells by reprogramming them, which has been demonstrated in mice and monkeys. Sinclair predicts that by 2035, age reversal therapies will be available for humans, with initial trials starting soon. He emphasizes the role of AI in accelerating research, allowing for rapid experimentation that would have taken decades in the past. Sinclair's lab is working on gene therapies that could potentially cure diseases like blindness and even reverse aging in tissues. The conversation touches on the costs of these therapies, with Sinclair aiming to reduce them significantly, potentially to just a few dollars per treatment. They also discuss the concept of "longevity escape velocity," where advancements in science could allow people to extend their lives indefinitely as they age. Sinclair highlights the importance of maintaining health through exercise, diet, and supplements, and shares his personal regimen, which includes various longevity-promoting substances. He stresses that the current medical system often focuses on treating symptoms rather than addressing the underlying causes of aging. The episode concludes with a discussion on the societal implications of increased longevity, including economic impacts and the need for a positive vision of the future. Sinclair believes that as we advance in age reversal technologies, we will need to rethink our approach to aging and health, ensuring that everyone has access to these innovations.

Investment in aging research is surging, promising advancements in chronic disease management. Stem cell research has evolved from embryonic controversies to synthetic biology, particularly with induced pluripotent stem cells (iPSCs), which can be derived from any somatic cell and reprogrammed. This breakthrough allows for standardized cell production, enhancing treatment efficacy. Recent trials have shown iPSCs can regenerate dopamine neurons in Parkinson's patients, indicating significant potential for neurodegenerative diseases. Current therapies include exosomes, which carry signaling molecules to promote healing, and are being explored for conditions like Alzheimer's. The U.S. lags in regulatory frameworks for stem cell therapies compared to countries like Japan, where such treatments are legal and regulated. Chronic diseases, including cancer, are largely lifestyle-related, with a focus on nutrition, exercise, and social connections being vital for health. Emerging therapies like follistatin gene therapy show promise in reducing biological age and enhancing muscle growth without exercise. The future may see organ regeneration through advanced techniques, while lifestyle modifications remain crucial. The conversation emphasizes the need for innovative approaches to health, bridging gaps in conventional medicine and addressing chronic conditions effectively.

Macular degeneration affects an estimated 11 million people in the U.S., with numbers expected to double due to aging populations and insufficient nutrient intake. Eye health relies on dietary diversity, emphasizing the importance of various nutrients. Leafy greens, particularly kale, are rich in macular carotenoids like lutein and zeaxanthin, which protect against light toxicity and age-related degeneration. Egg yolks and colorful vegetables, such as orange and yellow bell peppers, also contribute essential nutrients. Genetic factors play a role in macular degeneration risk, with over 50 genes identified. Lifestyle factors, including diet, smoking, and education level, significantly influence risk. Nutritional strategies, including adequate intake of antioxidants and omega-3 fatty acids from fish or algal oil, are crucial for eye health. Emerging therapies like red light therapy show promise in enhancing mitochondrial function and may benefit conditions like macular degeneration. Foods rich in antioxidants, such as berries and nuts, support both eye and brain health. Overall, a balanced diet rich in diverse nutrients is essential for maintaining eye health and preventing degeneration.

Glaucoma is the number one cause of irreversible blindness in the world, and Dr. Jeffrey Goldberg suggests vision restoration is imminent. The aim shifts from merely preventing loss to achieving supra-normal vision. He notes pro athletes often exhibit sharper vision and reflexes, and describes training with goggles that dim vision by missing some frames so athletes perform with reduced data; after training, returning to full vision yields faster reflexes and better hand–eye coordination. Cone cells refresh around 30–60 frames per second, so training at reduced data forces adaptation that can transfer to real play. Ferriss asks about presbyopia and vision basics. Goldberg explains aging lens stiffening around 40, the lens changes how we focus up close; he notes an accidental self-experiment with readers, leading to the concept of “supra normal” near vision. He identifies FDA-approved eye drops that constrict the iris to a smaller pupil, effectively creating a pinhole to improve near vision, allowing focus near and far. He then outlines eye anatomy: cornea, iris, pupil, lens for focusing; vitreous gel; retina with rods and cones; retinal processing and the neural path via retinal ganglion cells to the brain. He emphasizes cortex and brain plasticity with vision training. Goldberg discusses cutting-edge approaches: light therapies that affect mitochondria (red light helps mitochondrial health; violet light may slow myopia progression), and small doses for minutes daily rather than long exposure. Myopia control data shows some benefit; nicotinamide (vitamin B3) shows potential to restore vision in certain diseases; devices and augmented reality may train or augment vision outside the clinic. He highlights immune system roles in eye diseases; the microbiome's gut-eye axis; therapies targeting immune pathways and metabolic signaling are under study. He mentions psychedelics and other drugs as possible ways to modulate brain plasticity, with caution that dosing and training matter.